Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Substance P is a Major Mediator Causing Delayed Emesis in Anthracycline-Based Chemotherapy - Really?

  • Ulas, Arife (Ankara Ataturk Training and Research Hospital, Department of Medical Oncology) ;
  • Silay, Kamile (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research and Training Hospital, Department of Internal Medicine and Geriatrics) ;
  • Akinci, Sema (Ankara Ataturk Training and Research Hospital, Department of Hematology) ;
  • Yalcin, Bulent (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research and Training Hospital, Department of Medical Oncology)
  • Published : 2015.01.22
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9. https://doi.org/10.1200/JCO.2003.01.095
  2. McCrea JB, Majumdar AK, Goldberg MR, et al (2003). Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther, 74, 17-24. https://doi.org/10.1016/S0009-9236(03)00066-3
  3. Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M (2014). Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol, 32, 101-6. https://doi.org/10.1200/JCO.2013.51.4547
  4. Takahashi T, Nakamura Y, Tsuya A, et al (2011). Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol, 68, 653-9. https://doi.org/10.1007/s00280-010-1519-2
  5. Uchino J, Hirano R, Tashiro N, et al (2012). Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. Asian Pac J Cancer Prev, 13, 4187-90. https://doi.org/10.7314/APJCP.2012.13.8.4187